Some asked about my own feelings about the most exciting fields in oncology which could bring results. I should take a long moment to sit and summarize all the papers and also to check the moves of bit pharma companies...but right now I cannot (but I might use some AI to do the job soon!). But for not I will go with gut feelings and some observations.
Of course, what I am going to say is not complete and it's my opinion only, but it's an interesting topic to explore for the next future.
So, I think we are moving in a few different directions:
- ADCs (antibody drugs conjugates): most research from different sources is converging to positive or even very positive results....and big investments from huge companies like AZ (which is not Arizona!) are pointing there. Precision delivery of payloads and some help for standard chemo;
- radio theranostics: if CU-67 sar-bispsma keeps going on as it is going now, with incredibly good results and very low toxicity, I would not be surprised to see Pluvicto disappear in few years. Also in this case there are huge investments behind the scene;
- CRISPR: I am a big fan! In this case a lot is related to how successful the two therapies about sickle cells and thalassemia will be. To my knowledge till today (almost 6 months) a single treatment produced 100% remission and there are few lucky guys who don't need transfusions anymore. Expensive? Yes at the moment, even if not that expensive if you compare it to the cost of a cancer patient being alive for like 10 years. Cancer focused? Kind of, but not yet. It will really become hot and people will stop being scared about it (oh don't touch my genes please!!) if these first non oncological therapies will succeed. But it's a super hot subject when it comes to create platforms that can predict the behaviour of proteins and so on. for this purpose it's being already widely used in oncology;
- delivery techniques (apart from ADC): there is a LOT being done in this field, also because it's promising from a speed point of view. Such systems basically deliver existing or new chemotherapies in a highly selective way, giving them an extremely low toxicity, making them also more repeatable and usable also with fragile patients. This is the field where in the past 2 months I have seen the most new research. It's probably the cheapest option (apart for ADCs) and as I said, less stuff to be tested if it delivers known chemotherapies.
Immunotherapy is doing great things but not yet hitting PCa as we would like. Repurposing is making good steps forward but as adjuvant (which is important anyway).
Oh whichever comes first is welcome of course!! 😜😜😜
Have a great weekend!
Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT)
Taurine
Article: PSMA Theranostics Is Poised to Change Prostate Cancer Landscape
A NEW COMBINED DRUG PSMA-DOC HAS BEEN CREATED FOR THE TREATMENT OF PROSTATE CANCER!
Precision medicine-how effective?
